Abstract
To examine the benefits of steroid avoidance in adult living donor liver transplantation, we compared the clinical courses of nine recipients receiving basiliximab or daclizumab and 13 historical patients who received steroids. The 1-year patient and graft survival and the incidence of acute cellular rejection were similar in both groups. The side effects of immunosuppression tended to be more frequent in the steroid group. Hepatitis C virus (HCV)-RNA levels measured early after transplantation remained suppressed in the steroid-free group. Steroid avoidance was beneficial in the recipients, as both steroid side effects and recurrence of HCV could be avoided.
Publication types
-
Clinical Trial
-
Comparative Study
MeSH terms
-
Acute Disease
-
Adult
-
Aged
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal, Humanized
-
Basiliximab
-
Daclizumab
-
Disease-Free Survival
-
Female
-
Graft Rejection / drug therapy*
-
Graft Survival / drug effects
-
Hepatitis C, Chronic / surgery
-
Humans
-
Immunoglobulin G / administration & dosage
-
Immunoglobulin G / adverse effects
-
Immunosuppressive Agents / administration & dosage*
-
Immunosuppressive Agents / adverse effects
-
Liver Transplantation*
-
Living Donors*
-
Male
-
Middle Aged
-
Pilot Projects
-
Prospective Studies
-
Recombinant Fusion Proteins / administration & dosage*
-
Recombinant Fusion Proteins / adverse effects
-
Steroids / administration & dosage*
-
Steroids / adverse effects
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Immunoglobulin G
-
Immunosuppressive Agents
-
Recombinant Fusion Proteins
-
Steroids
-
Basiliximab
-
Daclizumab